↓ Skip to main content

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Overview of attention for article published in Arthritis & Rheumatology, June 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#29 of 3,088)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
42 news outlets
blogs
3 blogs
twitter
12 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Published in
Arthritis & Rheumatology, June 2023
DOI 10.1002/art.42519
Pubmed ID
Authors

Philip Mease, Philip Helliwell, Paula Silwinska‐Stanczyk, Malgorzata Miakisz, Andrew Ostor, Elena Peeva, Michael S. Vincent, Qiankun Sun, Vanja Sikirica, Randall Winnette, Ruolun Qiu, Gang Li, Gang Feng, Jean S. Beebe, David A. Martin

X Demographics

X Demographics

The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 6 17%
Student > Bachelor 5 14%
Other 3 8%
Professor 2 6%
Researcher 2 6%
Other 3 8%
Unknown 15 42%
Readers by discipline Count As %
Medicine and Dentistry 9 25%
Unspecified 6 17%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Immunology and Microbiology 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 2 6%
Unknown 15 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 324. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2023.
All research outputs
#104,810
of 25,639,676 outputs
Outputs from Arthritis & Rheumatology
#29
of 3,088 outputs
Outputs of similar age
#2,311
of 380,198 outputs
Outputs of similar age from Arthritis & Rheumatology
#1
of 87 outputs
Altmetric has tracked 25,639,676 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,088 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 380,198 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.